Sanofi loses vaccines chief Loew to Ipsen amid global attention on its COVID-19 project

Sanofi’s new CEO Paul Hudson has been making his mark in the company’s C-suite, and his latest round of executive shuffling will impact the company's top vaccines job—even as it’s preparing prepping its GlaxoSmithKline-partnered COVID-19 candidate.

David Loew, who has been leading vaccines unit Sanofi Pasteur since mid-2016, is jumping ship to fellow French drugmaker Ipsen as CEO, taking over from former chief executive David Meek, who is now CEO of Ferring Pharmaceuticals’ gene therapy spinout FerGene. Thomas Triomphe, who joined Sanofi Pasteur in 2004 and currently serves as the unit’s head of franchises and product strategy, will take his place.